Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of Durvalumab and Olaparib in platinum-treated advanced triple negative breast cancer (DORA)
KCT0003383Phase 2Completed
- Sponsor
- Duke University
- Start
- Apr 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, olaparib in breast cancer, sponsored by Duke University. Started Apr 2019; status: completed.
02
Drugs
durvalumabolaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on KCT0003383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003383.